Navigating Emerging Approaches for the Treatment of nAMD and DME

Author(s)/Faculty: Sophie J. Bakri, MD; Dilsher S. Dhoot, MD
Release Date: 2/10/2022Expiration Date: 2/9/2023
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 1
Content Type: MonographProvider:
Loss of adherence to dosing schedules and eyes that have an incomplete response to current anti-vascular endothelial growth factor (VEGF) therapies have contributed to suboptimal visual acuity outcomes in patients being treated for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). To address these unmet needs in the management of retinal diseases, novel delivery systems, gene therapies, and agents with unique mechanisms of action that extend the dosing frequency are currently being evaluated in clinical studies. These novel strategies have the potential to lengthen the dosing interval between treatments while enhancing visual acuity gains. In the CME eMonograph, experts in the field examine new evidence on novel delivery systems that reduce the need for frequent anti-VEGF injections, as well as evaluate emerging therapeutics with unique mechanisms of action that can lengthen the time between treatments for patients with nAMD and DME.